369 related articles for article (PubMed ID: 17634526)
1. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Lippman SM; Heymach JV
Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
[TBL] [Abstract][Full Text] [Related]
2. The convergence of cancer prevention and therapy in early-phase clinical drug development.
Abbruzzese JL; Lippman SM
Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755
[TBL] [Abstract][Full Text] [Related]
3. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
4. Oral cancer prevention and the evolution of molecular-targeted drug development.
Lippman SM; Sudbø J; Hong WK
J Clin Oncol; 2005 Jan; 23(2):346-56. PubMed ID: 15637397
[TBL] [Abstract][Full Text] [Related]
5. Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.
Kelloff GJ; Sigman CC
Nat Rev Cancer; 2007 Jul; 7(7):508-18. PubMed ID: 17568791
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention: from research to clinical oncology.
Veronesi U; Bonanni B
Eur J Cancer; 2005 Sep; 41(13):1833-41. PubMed ID: 16061373
[TBL] [Abstract][Full Text] [Related]
7. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
8. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
9. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Lippman SM; Lee JJ
Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of head and neck cancer.
Voravud N
J Med Assoc Thai; 1996 Mar; 79(3):185-93. PubMed ID: 8708501
[TBL] [Abstract][Full Text] [Related]
11. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
12. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemoprevention.
Hong WK; Lippman SM
J Natl Cancer Inst Monogr; 1995; (17):49-53. PubMed ID: 8573453
[TBL] [Abstract][Full Text] [Related]
14. Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Ranger-Moore J; Alberts DS; Montironi R; Garcia F; Davis J; Frank D; Brewer M; Mariuzzi GM; Bartels HG; Bartels PH
Eur J Cancer; 2005 Sep; 41(13):1875-88. PubMed ID: 16087328
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and surrogacy: relevance to chemoprevention.
Kensler TW; Davidson NE; Groopman JD; Muñoz A
IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy: for kids, too.
Corey SJ
Pediatr Blood Cancer; 2005 Oct; 45(5):623-34. PubMed ID: 15704219
[TBL] [Abstract][Full Text] [Related]
17. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
Crowell JA
Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
[TBL] [Abstract][Full Text] [Related]
18. Lycopene in cancer prevention and treatment.
Seren S; Lieberman R; Bayraktar UD; Heath E; Sahin K; Andic F; Kucuk O
Am J Ther; 2008; 15(1):66-81. PubMed ID: 18223356
[TBL] [Abstract][Full Text] [Related]
19. Cancer prevention: recent progress and future opportunities.
Weinstein IB
Cancer Res; 1991 Sep; 51(18 Suppl):5080s-5085s. PubMed ID: 1884384
[TBL] [Abstract][Full Text] [Related]
20. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
